Society guideline links: Menopause

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately.

●(See "Society guideline links: Primary ovarian insufficiency".)

●(See "Society guideline links: Osteoporosis".)

●(See "Society guideline links: Breast cancer".)

●(See "Society guideline links: Primary prevention of cardiovascular disease".)

International

●North American Menopause Society (NAMS): Position statement on nonhormone therapy (2023)

●NAMS: Position statement on hormone therapy (2022)

●NAMS: Position statement on management of osteoporosis in postmenopausal women (2021)

●Endocrine Society (ES): Pharmacological management of osteoporosis in postmenopausal women, update (2020)

•ES: Pharmacological management of osteoporosis in postmenopausal women (2019)

●NAMS: Position statement on the genitourinary syndrome of menopause (2020)

●NAMS and International Society for the Study of Women's Sexual Health (ISSWSH): Consensus recommendations for the management of genitourinary syndrome of menopause in women with or at high risk for breast cancer (2018)

●Endocrine Society (ES): Scientific statement on compounded bioidentical hormones in endocrinology practice (2016)

●International Menopause Society (IMS): Recommendations on women's midlife health and menopause hormone therapy (2016)

●Revised global consensus statement on menopausal hormone therapy (2016)

●ES: Clinical practice guideline for the treatment of symptoms of the menopause (2015)

●NAMS: Statement on continuing use of systemic hormone therapy after age 65 (2015)

●ES: Clinical practice guideline on androgen therapy in women – A reappraisal (2014)

●ISSWSH and NAMS: Genitourinary syndrome of menopause – New terminology for vulvovaginal atrophy (2014)

●NAMS: Recommendations for clinical care of midlife women (2014)

●IMS: Recommendations for the management of postmenopausal vaginal atrophy (2010)

Canada

●Choosing Wisely Canada: Don't routinely order hormone levels including estradiol, progesterone, follicle-stimulating hormone and luteinizing hormone in postmenopausal women or after a hysterectomy, either to diagnose menopause or to manage hormone therapy (2021)

●Society of Obstetricians and Gynaecologists of Canada (SOGC): Clinical practice guideline on intravaginal laser for genitourinary syndrome of menopause and stress urinary incontinence (2018)

●SOGC: Canadian consensus on female nutrition – Adolescence, reproduction, menopause, and beyond (2016)

●SOGC: Clinical practice guideline on managing menopause (2014)

●SOGC: Clinical practice guideline on osteoporosis in menopause (2014)

United States

●American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE): Clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, update (2020)

●American College of Obstetricians and Gynecologists (ACOG): Committee opinion on hormone therapy and heart disease (2013, reaffirmed 2020)

●ACOG and the American Society for Reproductive Medicine (ASRM): Committee opinion on compounded bioidentical menopausal hormone therapy (2012, reaffirmed 2020)

●ACOG: Committee opinion on the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding (2018)

●ACOG: Committee opinion on postmenopausal estrogen therapy – Route of administration and risk of venous thromboembolism (2013, reaffirmed 2017)

●US Preventive Services Task Force (USPSTF): Final recommendation statement – Hormone therapy in postmenopausal women: Primary prevention of chronic conditions (2017)

●Society of Gynecologic Surgeons (SGS): Vaginal estrogen use in postmenopausal women with pelvic floor disorders – Systematic review and practice guidelines (2015)

●ACOG: Practice bulletin on the management of menopausal symptoms (2014)

●SGS: Vaginal estrogen for genitourinary syndrome of menopause – A systematic review (2014)

●American Heart Association (AHA): Science advisory on soy protein, isoflavones, and cardiovascular health (2006)

Europe

●European Menopause and Andropause Society (EMAS): Clinical guides

United Kingdom

●British Menopause Society (BMS): Consensus statements

●National Institute for Health and Care Excellence (NICE): Guideline on menopause – Diagnosis and management (2015, updated 2019)

●NICE: Quality standard on menopause (2017)

●Choosing Wisely UK: Faculty of Sexual and Reproductive Health – If a woman over the age of 45 years with typical symptoms of menopause, such as hot flushes and sweats and if her periods have become irregular, much lighter or have stopped, further bloods tests to check hormone levels are not usually necessary (2016)

Japan

●[In Japanese] Japan Society of Obstetrics and Gynecology (JOGS): Hormone replacement therapy guideline (2017)